GM1 Oligosaccharide Modulates Microglial Activation and α-Synuclein Clearance in a Human In Vitro Model

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Neuroinflammation, driven by microglial activation and alpha-synuclein (αSyn) aggregation, is central to Parkinson's disease (PD) pathogenesis.
• The neuroprotective potential of GM1 ganglioside's oligosaccharide moiety (OligoGM1) in PD models is known, but its direct anti-inflammatory effects require further definition.

Purpose of the Study:

• To investigate OligoGM1's ability to modulate microglial activation and αSyn handling in a human in vitro PD model.
• To assess OligoGM1's impact on microglial activation markers, intracellular αSyn accumulation, and cytokine release.

Main Methods:

• Human embryonic microglial (HMC3) cells were challenged with αSyn pre-formed fibrils (PFFs) with or without OligoGM1 pre-treatment.
• Immunofluorescence and ELISA were used to measure microglial activation markers (Iba1, TREM2), intracellular αSyn, and cytokine (IL-6) release.

Main Results:

• OligoGM1 did not affect basal microglial morphology or cytokine release.
• αSyn challenge increased microglial activation markers, intracellular αSyn, and pro-inflammatory cytokine release.
• OligoGM1 pre-treatment significantly reduced Iba1(+) cell counts/area, intracellular αSyn in TREM2(+) microglia, and IL-6 release.

Conclusions:

• OligoGM1 selectively attenuates αSyn-induced microglial activation and enhances αSyn clearance.
• OligoGM1 demonstrates potential as a multitarget therapeutic candidate for PD by modulating glial reactivity and neuroinflammation.